Reprieve Cardiovascular, a Milford, MA-based development stage company focused on an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, raised $42M in Series A funding.
The round was led by Lightstone Ventures and Sante Ventures and joined by Deerfield Management, Genesis Capital, and Arboretum Ventures.
The company intends to use the funds to advance its clinical and development programs, including the ongoing FASTR trial and its upcoming pivotal trial.
Led by CEO Mark Pacyna, Reprieve Cardiovascular is developing therapies that aim to improve the lives of more than 25 million heart failure patients around the world. It is bringing intelligence to decongestion management to safely accelerate fluid removal for heart failure patients. In 2022, the company initiated the FASTR Trial (pilot study) to compare decongestive therapy administered by the Reprieve Decongestion Management System to Optimal Diuretic Therapy in the treatment of patients diagnosed with acute decompensated heart failure.
FinSMEs
20/02/2024